| ABSTRACT Objective::To observe the clinical benefit response, adverse reactions and immune function on late non small cell lung cancer patients (NSCLC) with sodium cantharis vitamin B6 injection and DP chemotherapy. Methods::42 cases with ⅢB stage or Ⅳ stage of non small cell lung cancer (NSCLC) were divided into 2 groups randomly.The control group was treated by pure DP chemotherapy and the observation group, treated by sodium cantharis vitamin B6 injection 0.5mg·d-1,ivd based on the control group.After all the patients completed their three cycles of chemotherapy at least,the clinical benefit response rate, immune function indicators and incidence of adverse reactions were observed.Results::The positive indicators of clinical benefit response of the observation group was significantly higher than those of the control group(P<0.05).About the immune function,the NK cell activity and the T4/T8 declined significantly before and after the treatment of the control group（P＜0.05）, but increased significantly before and after the treatment of the observation group（P＜0.05）and the rangeability was higher than that of the control group（P＜0.05）.About the leukocytopenia, the observation group was far below the control group,which had significant differences between the two groups (P<0.05),and there was no statistically significant difference in other indicators.Conclusion::Sodium cantharids vitamin B6 and combined with DP chemotherapy with its higher clinical benefit response rate of late non small cell lung cancer could improve chemotherapy tolerance and the medical compliance of patients and reduce opioid dose with high safety; therefore, it is worth popularizing. |
